The collaboration will leverage the technologies of both companies, expanding their research capabilities in translational oncology. The collaboration will offer new mouse cancer and leukemia models based on Crown Bioscience’s GEMM platform, its new human xenografts, as well as the current PDX and CDX platforms (Cell line Derived Xenograft).
Dr. Jean-Pierre Wery, Crown’s president,said, “Crown plays a leading role in providing cutting-edge translational platforms and cost effective drug developmentsolutions for almost all top pharmaceutical companies worldwide. Crown is very happy to partner with NRCMM, the leading research institute for genetically engineered animals in China. This partnership will offer world-class translational oncology services, and ultimately benefit cancer patients around the world. This collaboration will further strengthen Crown’s leading position as the oncology translational medicine partner for drug discovery organizations worldwide.”